



**Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC#36-22) 12/13/2022 Zosano Pharma
Corporation (ZSANQ)**

Notice has been received that the above Company's Chapter 11 Plan of Liquidation became effective on 12/07/2022. Pursuant to the plan, On the Effective Date, all Interests in the Debtor shall be cancelled and released without any distribution and the Debtor shall be dissolved. For more information see the Company's Chapter 11 Plan of Liquidation.¹

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist of a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Operations- 1-866-776-0800.

¹ See *e.g.*, In re: Zosano Pharma Corporation, *et al.*, Debtors. Case No. 22-10506 (JKS) (Jointly Administered) Chapter 11 Plan of Liquidation for Zosano Pharma Corporation and Certain of its Affiliates.